Company Overview
About Bio-Techne
Bio-Techne Corporation is a Minneapolis, Minnesota-based life sciences tools company — publicly traded on NASDAQ (NASDAQ: TECH) as an S&P 500 Health Care component — developing, manufacturing, and selling biological reagents, proteins, antibodies, assay kits, analytical instruments, and spatial biology tools for pharmaceutical drug discovery, bioprocessing, academic research, and clinical diagnostics through approximately 3,000 employees across 34 global locations with an annual revenue of $1.19 billion in fiscal year 2024. In Q2 fiscal 2025, Bio-Techne reported organic revenue growth of 9% to $297 million, demonstrating recovery from the funding-constrained biotech environment of 2023-2024. The company operates through two segments: Protein Sciences (approximately 75% of revenue, including the R&D Systems portfolio of 500,000+ life science products — cytokines, growth factors, antibodies, ELISAs, and recombinant proteins — as well as ProteinSimple analytical instruments and Tocris Bioscience chemical biology tools) and Diagnostics and Genomics (approximately 25%, including Advanced Cell Diagnostics' RNAscope technology for gene expression visualization in intact tissue and Lunaphore's COMET spatial biology automation platform acquired in 2023). Bio-Techne launched approximately 800 new products in fiscal 2024 and maintains a catalog of 6,000+ recombinant proteins spanning 35 species. The company has a market capitalization of approximately $9.59 billion.
Business Model & Competitive Advantage
Bio-Techne's life science tools model addresses the biological reagent reproducibility and traceability problem that pharmaceutical and academic researchers face when conducting experiments that must be repeated across years, labs, and geographies: a drug discovery team screening compounds for activity against a cytokine target (e.g., IL-6, TNF-alpha) requires reference proteins and antibody reagents that perform consistently lot-to-lot, species-to-species, and assay-to-assay — otherwise, a lead compound validated in Year 1 may fail in Year 3 because the reference protein standard used to measure activity degraded or changed manufacturing process. R&D Systems' position as the gold-standard supplier for cytokine proteins and ELISA kits (used in published peer-reviewed papers across 25,000+ publications) creates the citation network that makes switching to a lower-cost reagent supplier a scientific risk that academic and biopharma researchers prefer to avoid. The RNAscope spatial biology platform (enabling visualization of RNA expression in specific cells within intact tissue sections rather than bulk RNA-seq that averages across thousands of cells) addresses the drug developer's need to understand drug target expression at cellular resolution within tumor microenvironments and brain tissue.
Competitive Landscape 2025–2026
In 2025, Bio-Techne competes in the life science reagents, protein biology, and spatial biology tools market with Thermo Fisher Scientific (NYSE: TMO, $43B revenue, Invitrogen/Gibco life science tools), Merck KGaA/MilliporeSigma (private, laboratory chemicals and biologics, €22B revenue), and 10x Genomics (NASDAQ: TXG, spatial transcriptomics platforms, $157M revenue) for biopharma research account penetration, academic core lab adoption, and pharmaceutical quality control reagent supply. Bio-Techne's high-margin reagent model (catalog life science products sold to research labs at gross margins of 70%+) is more durable than instrument hardware because consumable reagent purchasing decisions are made at the bench scientist level based on scientific validation rather than IT procurement cycles. The COMET spatial biology platform (Lunaphore, 2023 acquisition) positions Bio-Techne against 10x Genomics and Akoya Biosciences in the high-growth tissue spatial biology market that pharmaceutical companies use for biomarker discovery and drug mechanism of action studies. The 2025 strategy focuses on resuming organic growth momentum after 2023-2024 biotech funding headwinds, expanding the spatial biology platform into clinical research and companion diagnostics, and growing the bioprocessing reagents business as cell therapy manufacturing scales.
The Bio-Techne Story
Founders
Recent Activity
View all →Company Timeline
Major milestones in Bio-Techne's journey
Leadership Team
Meet the leaders behind Bio-Techne
Kim Kelderman
Kim Kelderman has served as President and CEO since February 1, 2024, and is a member of the Board of Directors. She joined Bio-Techne in April 2018 as President of Diagnostics and Genomics, and served as Chief Operating Officer from November 2023 to January 2024, bringing extensive experience in life sciences and strategic growth.
James T. Hippel
James Hippel has served as Chief Financial Officer since April 1, 2014. As Executive Vice President and CFO, he oversees all financial operations, investor relations, and strategic financial planning for the corporation.
Matthew F. McManus
Matthew McManus joined Bio-Techne as President of Diagnostics and Genomics on January 8, 2024. He leads the company's diagnostics segment, which includes Advanced Cell Diagnostics and the RNAscope technology platform.
Cheryl Bethune
Cheryl Bethune joined Bio-Techne in September 2024 as Chief Human Resources Officer. She leads talent acquisition, employee development, diversity initiatives, and corporate culture programs across the global organization.
Martin Wirtz
Martin Wirtz joined Bio-Techne in July 2024 in a senior strategy position, helping guide the company's long-term strategic planning, mergers and acquisitions, and market expansion initiatives.
Robert S. Kapito
Former CEO Chuck Kummeth served as Chief Executive Officer from March 2013 until his retirement in January 2024, leading the company through a transformative period of growth including 14 strategic acquisitions in five years.
Key Differentiators
Market Leader
Bio-Techne is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $1.19B in revenue, Bio-Techne operates at enterprise scale with proven market validation.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Pfizer
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The compan
Moderna
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép
Amgen
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologic
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Zocdoc
Zocdoc operates a two-sided marketplace connecting patients with physicians, dentists, and mental health providers who accept their specific insurance and have real-time appointment availability. Pati
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Compare Bio-Techne with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Bio-Techne? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Bio-Techne Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Bio-Techne vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →